Aug 19, 2026 06:45AM
Aug 18, 2026 09:01AM
Aug 18, 2026 09:00AM
Jul 20, 2026 09:01AM
Jul 20, 2026 09:00AM
Jul 14, 2026 07:00AM
Jul 13, 2026 09:01AM Oncolytics to meet FDA on registrational path for REO 033 trial
Jul 13, 2026 09:00AM
Jun 16, 2026 09:00AM
Jun 16, 2026 09:00AM
Jun 2, 2026 09:00AM
Jun 2, 2026 09:00AM
Jun 1, 2026 09:03AM
Jun 1, 2026 09:00AM Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
May 26, 2026 06:59AM
May 22, 2026 09:00AM
May 14, 2026 10:55AM
May 14, 2026 10:55AM
May 4, 2026 09:00AM
Apr 27, 2026 08:10AM
Apr 27, 2026 08:10AM Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Apr 10, 2026 06:49AM
Apr 6, 2026 09:00AM
Apr 6, 2026 09:00AM
Apr 1, 2026 09:02AM
Apr 1, 2026 09:00AM
Mar 19, 2026 11:00AM
Mar 19, 2026 09:00AM Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Mar 2, 2026 09:02AM
Mar 2, 2026 09:00AM
Feb 24, 2026 09:01AM
Feb 24, 2026 09:00AM
Feb 17, 2026 10:48AM
Feb 5, 2026 09:26AM
Feb 4, 2026 08:50AM Oncolytics receives FDA fast track for colorectal cancer treatment
Feb 4, 2026 08:50AM
Jan 15, 2026 04:01PM
Jan 14, 2026 10:39AM
Jan 14, 2026 09:00AM
Jan 12, 2026 10:14AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Jan 9, 2026 09:02AM
Jan 9, 2026 09:00AM
Jan 8, 2026 12:08PM
Jan 8, 2026 09:02AM
Jan 8, 2026 09:00AM
Jan 7, 2026 12:15PM
Jan 7, 2026 09:01AM Oncolytics Biotech adds three experts to gastrointestinal advisory board
Jan 7, 2026 09:00AM

329,752 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All